[Telbivudine]Clinical features and risk factors of creatine kinase elevations an

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01412.x/abstract>

Clinical features and risk factors of creatine kinase elevations and myopathy
associated with telbivudine

X. J. Zou, X. Q. Jiang, D. Y. Tian
Article first published online: 23 DEC 2010

DOI: 10.1111/j.1365-2893.2010.01412.x
© 2010 Blackwell Publishing Ltd
Issue

Journal of Viral Hepatitis
Early View (Articles online in advance of print)

Summary.  With the extensive use of telbivudine, more and more studies
reported its association with creatine kinase (CK) elevations and myopathy.
However, clinical features of these adverse effects were poorly understood. The
aim of the present study was to investigate the clinical features and risk
factors of CK elevations and myopathy associated with telbivudine. The serum CK
levels of 200 patients who were treated with telbivudine for chronic hepatitis B
(CHB) between January 2007 and July 2010 were monitored and analysed along with
clinical manifestations. The 3-year cumulative incidence of CK elevations and
myopathy was 84.3% and 5%, respectively. CK elevations occurred more frequently
in men than in women, and patients aged ≤45 years and with negative HBeAg had
higher incidence of CK elevations. There was no difference in CK elevations
among patients with different HBV DNA levels. Male, younger age and HBeAg
negativity were independent predictors of CK elevations by multivariate Cox
regression analysis. There was no association between the occurrence of myopathy
and variables including age, sex, HBeAg and HBV DNA. No risk factors of myopathy
were identified. CK elevations usually occurred 21 months after starting
treatment, and most patients resolved spontaneously without interruption of
telbivudine therapy except three patients who had to switch to other agents. In
conclusion, CK elevations are common adverse reactions associated with
telbivudine therapy, while myopathy is rare. Male, younger age and HBeAg
negativity might be risk factors of CK elevations.
                           
临床特点及肌酸激酶升高和肌病的危险因素
与替比夫定

X.J. 邹, X.Q.江，D.Y. Tian
Article首次发表时间：2010年12月23号

分类号：10.1111/j.1365-2893.2010.01412.x
© 2010布莱克韦尔出版有限公司
发行

作者：病毒性肝炎
厄尔利维尤（第预先在网上打印）

综述。随着替比夫定，越来越多的研究广泛使用
报告与肌酸激酶（CK）升高和肌病协会。
然而，这些不利影响的临床特点是知之甚少。该
本研究的目的是探讨其临床特点及风险
CK的升高和肌病相关因素的替比夫定。血清CK
200谁是病人与替比夫定治疗慢性乙型肝炎的水平
（彰银）2007年1月至2010年7月进行了监测和分析以及
临床表现。 3年累计发生率升高与对照
肌病为84.3％和5％，分别为。对照升高更加频繁发生
女性比男性，年龄≤45岁患者和HBeAg阴性了
海拔较高的发病率对照。有没有对照海拔差异
在不同HBV DNA水平与患者。男性，年龄较轻，e抗原
消极性是由多变量Cox的CK升高的独立危险因素
回归分析。没有发生肌病之间的关联
包括年龄，性别，HBeAg和HBV DNA的变量。无肌病的危险因素
被确定。对照升高通常发生在21个月开始
处理，解决，不中断地自发大多数患者
替比夫定治疗的患者，除了三名谁不得不改用其他药物。在
总之，对照海拔都与常见的不良反应
替比夫定治疗，而肌病是罕见的。男性，年龄较轻，e抗原
可能是消极的CK升高的危险因素。

wonder4078

了解下吧